Clinical trial • Phase 0|Phase III • Neurology
Cannabidiol for Glioblastoma
Phase 0|Phase III trial of Cannabidiol for Glioblastoma. 7 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Glioblastoma
- Trial Stage
- Phase 0|Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 26-07-2024
- First CTIS Authorization Date
- 22-10-2024
Trial design
Phase 0|Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 7
Eligibility
Recruits 7 No vulnerable populations selected; consent or assent handling not specified..
- Vulnerable Population
- No vulnerable populations selected; consent or assent handling not specified.
Recruitment
- Planned Sample Size
- 7
- Recruitment Window Months
- 34
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 7
Netherlands
- Earliest CTIS Part Ii Submission Date
- 16-10-2024
- Latest Decision Or Authorization Date
- 30-07-2025
- Processing Time Days
- 287
- Number Of Sites
- 1
- Number Of Participants
- 7
Sites
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Neurology
- Principal Investigator Name
- Martin van den Bent
- Principal Investigator Email
- m.vandenbent@erasmusmc.nl
- Contact Person Name
- Martin van den Bent
- Contact Person Email
- m.vandenbent@erasmusmc.nl
- Number Of Participants
- 7
Sponsor
Primary sponsor
- Full Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- CBD (cannabidiol)
- Active Substance
- Cannabidiol
- Modality
- Small molecule
Related trials
Other published trials that may interest you.